In-vitro activity of purpuromycin and MDL 63,604 against microorganisms that cause vaginitis and vaginosis.
Purpuromycin and its semi-synthetic derivative MDL 63,604 had in-vitro activity similar to that of amphotericin B against isolates of Candida albicans. MDL 63,604 had activity similar to that of metronidazole against Trichomonas vaginalis. Both compounds were very active against most species of Gram-positive and Gram-negative anaerobes and against Gardnerella vaginalis. MDL 63,604 had significantly lower MICs than purpuromycin against T. vaginalis and most of the bacteria, probably due to antagonism of purpuromycin's activity by medium supplements (blood or serum). Purpuromycin or related compounds may have a potential role in the topical treatment of vaginitis and vaginosis.
Goldstein
B P
BP
Lepetit Research Center, Marion Merrell Dow Research Institute, Gerenzano Varese, Italy.
King
A
A
Ripamonti
F
F
Trani
A
A
Phillips
I
I
D000666:Amphotericin B / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D005260:Female; D006194:Gardnerella vaginalis / Q000187:drug effects*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009285:Naphthoquinones / Q000494:pharmacology*; D013141:Spiro Compounds / Q000494:pharmacology*; D014246:Trichomonas vaginalis / Q000187:drug effects*; D014627:Vaginitis / Q000188:drug therapy / Q000382:microbiology; D016585:Vaginosis, Bacterial / Q000188:drug therapy / Q000382:microbiology
D000935:Antifungal Agents; C099080:MDL 63604; D009285:Naphthoquinones; D013141:Spiro Compounds; C009115:purpuromycin; D000666:Amphotericin B